Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Moody's Corporation (MCO) Price & Performance

Inovio Pharmaceuticals IncTrade
Moody's CorporationTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Moody's Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Moody's Corporation trades at $476.73 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 1050.5× Inovio Pharmaceuticals Inc's market cap, and Moody's Corporation pays a 0.86% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

INOMCO
Market Cap
$78.55M$82.52B
Sector
HealthFinancials
52-Week High
$2.87$539.61
52-Week Low
$0.66$412.23
Enterprise Value
$49.56M$88.54B
Dividend Yield
0.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Moody's Corporation

Moody's Corporation (MCO) trades at $477.00, down 0.24% on the day, with strong fundamentals including 80.15% ROE and 34.25% net margin. The stock shows bearish technical signals but maintains robust earnings momentum with three consecutive quarterly beats. Revenue growth accelerated to $7.72 billion in 2025, while analyst consensus remains bullish with a $561.88 price target representing 18% upside potential.

MCO presents a compelling growth story with premium valuation metrics (P/E 30.23) justified by consistent earnings outperformance and dominant market position. Key risks include sensitivity to debt issuance cycles and elevated valuation multiples. The combination of strong profitability, analyst support, and dividend payments supports a positive long-term outlook despite near-term technical weakness.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Moody's Corporation

Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.

Read more on MCO